The results of phase III study ORIENT-31 [12] prospectively validated that the combination therapy of ICI, anti-angiogenesis, and chemotherapy could bring significant survival benefits to NSCLC patients with EGFR-TKI resistance (median PFS: 7.2 vs. 4.3 months, HR,0.59), compared to standard chemotherapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.